文献速递肝肾功能剂量调整特殊人群用药

群体药动学分析辅助苯乙酸L-鸟氨酸盐剂量选择

Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid.
PubMed 文献 · Clin Pharmacokinet · 2021-11-17

本研究基于四项临床试验的血浆浓度数据,建立L-鸟氨酸、苯乙酸和苯乙酰谷氨酰胺的群体药动学模型,评估体重、种族和肝肾功能对暴露的影响以支持III期剂量选择。结果显示体重和肝功能是苯乙酸暴露的显著协变量,肾功能不全显著降低苯乙酰谷氨酰胺排泄但不影响苯乙酸和游离氨水平,固定剂量方案需特别关注体重≤50 kg和严重肝损伤患者。

要点

  • 体重和肝功能是决定苯乙酸暴露的显著协变量。
  • 肾功能不全显著降低苯乙酰谷氨酰胺排泄,但不影响苯乙酸和游离氨水平。
  • 固定剂量方案需特别关注体重≤50 kg和严重肝损伤患者。

核心结论

  • 体重和肝功能是苯乙酸暴露的显著协变量,固定剂量方案需特别关注体重≤50 kg和严重肝损伤患者。

研究设计与样本

  • 基于四项临床试验(健康受试者、稳定肝硬化患者、住院肝硬化伴肝性脑病成人患者)的血浆浓度数据建立群体药动学模型。

主要发现

  • 体重和肝功能是决定苯乙酸暴露的显著协变量。
  • 校正体重后,白种人和亚洲人群的苯乙酸暴露无差异。
  • 肾功能不全显著降低苯乙酰谷氨酰胺排泄,但不影响苯乙酸和游离氨水平。
  • 探索性建模提示L-鸟氨酸可能增强氨的清除。

关键数值与推荐

  • 固定剂量算法下,体重≤50 kg和严重肝损伤患者需特殊考虑。

临床怎么用

  • 临床选用固定剂量时,应关注体重≤50 kg和严重肝损伤患者的暴露差异。

局限性

  • 目标患者II期研究未设计用于剂量探索,临床数据非常有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: L-Ornithine phenylacetate is an intravenous formulation of the L-ornithine salt of phenylacetic acid under development for the treatment of hepatic encephalopathy. Very limited clinical data in patients are available, with a phase II study in target patients not designed for dose finding, to support phase III dose selection in a global development program. The objective of the present population pharmacokinetic modeling and simulation was to evaluate dose selection for target patient populations with a low body weight, ethnicity, and hepatic impairment in a global clinical study. METHODS: A population pharmacokinetic model was developed based on plasma concentrations of L-ornithine, phenylacetic acid, and phenylacetylglutamine data from four clinical trials in healthy subjects and patients with stable cirrhosis or hospitalized adult patients with liver cirrhosis and hepatic encephalopathy. A covariate analysis was conducted to identify source of variability to support dose selection for global clinical development of L-ornithine phenylacetate. Phenylacetylglutamine formation in the pharmacokinetic model also quantified pharmacodynamic effects measured by ammonia removal. RESULTS: Body weight and hepatic function were significant covariates determining phenylacetic acid exposure. After accounting for body weight, there was no difference between tested Caucasian and Asian populations in phenylacetic acid exposure. Renal dysfunction significantly reduced phenylacetylglutamine excretion. However, renal impairment had no impact on plasma phenylacetic acid and free ammonia levels. Exploratory modeling suggested that L-ornithine might enhance the removal of ammonia. CONCLUSIONS: With a flat dosing algorithm, special consideration must be given to patients with a small body size (i.e., body weight ≤ 50 kg) and severe hepatic impairment.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Wang X, Vilchez RA. Population Pharmacokinetic Analysis to Assist Dose Selection of the L-Ornithine Salt of Phenylacetic Acid. Clin Pharmacokinet. 2021. PMID: 34786649. doi:10.1007/s40262-021-01075-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。